abstract |
Embodiments of the disclosure provide methods and compositions related to improving cardiomyocyte production by exposing starting cells to ETV2 and/or VEGF. The starting cells in specific embodiments are fibroblasts and/or endothelial cells, and following exposure to ETV2 and/or VEGF the resultant cells are exposed to one or more cardiomyocyte transdifferentiation factors, such as GATA4, myocyte enhancer factor-2c (Mef2c), T-box transcription factor 5 (TBX5), or a combination thereof. The produced cardiomyocytes are provided to individuals in need thereof, in particular embodiments. |